2024-04-02

1. Executive Summary of the Month
In March, there were a total of 40 licensing and cooperation deals signed, marking a slight decrease compared to February. Within China pharma market, 8 deals were sealed, comprising 4 out-licensing deals, 3 domestic deals and 1 in-licensing deal. The most significant deal of the month in China market was between Biotheus and Hansoh Pharmaceutical, with a total deal value of $706.5 million.
On a global scale, there were 32 licensing and cooperation deals signed in March. The most prominent global deal was between AriBio and an undisclosed company, which boasted an upfront payment of $90 million and a total deal value of $770 million.
2024年3月,全球医药市场共签署了40项资产授权和合作协议,与2月份相比小幅减少。其中,中国医药市场共达成8笔交易,包括4笔出海交易、3笔引进交易和1笔国内交易。本月中国市场最重要的交易来自普米斯与翰森制药达成的交易,总价值为7.065亿美元。
在全球范围内,3月份签署了32项资产授权和合作协议。最大的一笔交易是AriBio与一家未披露名字的公司达成的交易,预付款为9000万美元,总价值为7.7亿美元。








2.Licensing Deals






2a. Out-Licensing Deals




2b. In-Licensing Deals

2c. Domestic Licensing Deals



3. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年,作为新型投资和投行咨询机构,致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购,雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络,在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队,覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历,为客户交易提供强力支持。雅法总部位于上海,在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
ACCESS CHINA

Event Name: ACCESS CHINA Partnering Forum @BIO
Date & Time: June 3-20, 2024
Venue: San Diego & Online
Content: Keynote Speeches, Panel Discussion, Virtual Roadshows, Dinner Reception, 1X1 meetings
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs.Registration Link: https://jinshuju.net/f/AqkB9m